Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs. Glibenclamide on circulating EPCs in type 2 diabetes
2012-005399-32Phase 4Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin arm with Glibenclamide arm (2 arms). Primary endpoint: Change in circulating endothelial progenitor cell (EPC) number. Started Jan 2013; status: completed.
02
Drugs
vildagliptinglibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-005399-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005399-32.